Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus AI (NASDAQ:TEM) announced the national launch of its OneOme pharmacogenomics (PGx) testing solution, fully integrated following Tempus’ November 2025 acquisition of OneOme. The offering delivers genetic insights to help optimize medication safety, dosing and toxicity risk assessment, particularly in oncology.
The launch features OneOme’s flagship RightMed Comprehensive 27-gene germline PGx laboratory-developed test, plus single-gene DPYD and UGT1A1 assays. According to Tempus, results are typically available in under five days from sample receipt, and the tests are embedded into the broader Tempus ecosystem, enabling clinicians to review drug-gene interactions alongside tissue and liquid biopsy sequencing at the point of care. Tempus highlights recent FDA labeling updates recommending DPYD testing before fluoropyrimidine therapies, where external research indicates nearly 30% of patients experience severe toxicities.
Tempus AI (NASDAQ: TEM) has entered a definitive agreement to acquire Personalis (NASDAQ: PSNL), valuing Personalis at an enterprise value of $1.5 billion net of Tempus’ existing stake. Personalis shareholders will receive $16.25 per share, a 6% premium to the prior Friday close and 28% to the unaffected 30‑day VWAP.
The deal is structured as a 100% stock transaction, with Tempus able to elect up to 50% of consideration in cash, financed by cash on hand and borrowings under existing credit facilities. Personalis holders will receive a floating exchange ratio of Tempus shares, capped at 0.3356 per Personalis share, to be finalized closer to closing.
The acquisition integrates Personalis’ tumor‑informed NeXT Personal MRD technology, which has Medicare coverage in three indications, into Tempus’ AI‑enabled precision oncology and multimodal data platform. According to Tempus, this expands its capabilities across the cancer care continuum and positions both companies in the emerging $20 billion MRD market. Closing is expected in late 2026 or early 2027, subject to Personalis shareholder and regulatory approvals. Personalis reported preliminary Q2 revenue of $22.4 million and delivered 10,384 clinical tests, a 33% sequential test volume increase.
Tempus (NASDAQ:TEM) reported real-world results from the multi-center Articulate Pro study, published in Nature Digital Medicine, evaluating the Paige Prostate Suite within UK National Health Service workflows. Expert histopathologists at three NHS trusts used the AI suite to assist in reporting prostate biopsies from over 1,000 patients.
According to Tempus, AI-assisted review led pathologists to reassess and update diagnoses or Grade Groups in 5% of patients, with 1.3% of changes significant enough to potentially alter clinical management. The deployment was associated with quicker diagnostic turnaround, fewer immunohistochemistry staining requests, and reduced laboratory workload.
Tempus (NASDAQ:TEM) will report second quarter 2026 financial results on Thursday, July 30, 2026, for the quarter ended June 30, 2026.
Management will host a 4:30 p.m. ET conference call and live webcast, accessible via the Tempus investor relations website.
Tempus (NASDAQ:TEM) announced a research collaboration with Angiosarcoma Awareness to advance data-driven studies in angiosarcoma, a rare and aggressive cancer diagnosed in about 1,000 U.S. patients annually.
The effort leverages roughly 600 de-identified angiosarcoma records with paired DNA/RNA sequencing and clinical data to explore disease biology and potential therapeutic opportunities, building on the patient-partnered Angiosarcoma Project launched in 2017.
Tempus (NASDAQ:TEM) reported multi-center validation of its FDA-cleared ECG-AF software for predicting one-year atrial fibrillation or flutter risk. The study of 4,017 patients across three clinical sites, published in Heart Rhythm, showed the AI-derived risk score exceeded pre-specified performance thresholds, supporting regulatory clearance.
The tool analyzes resting 12-lead ECGs from patients 65+ without prior AF or certain devices, and is intended as a decision-support aid alongside other clinical information, not for monitoring or standalone diagnosis or treatment.
Tempus (NASDAQ:TEM) subsidiary Ambry Genetics reported peer-reviewed research in Genetics in Medicine Open on its ExomeReveal RNA testing workflow. The study reviewed nearly 2,000 exome variants and found that integrating targeted RNA analysis can help clarify variants of uncertain significance and improve diagnostic clarity for genetic disease.
About one in ten variants were suspected splice-affecting; roughly 8% qualified for RNA testing. Among participants with uncertain results who underwent follow-up RNA analysis, some variants were upgraded to provide a diagnosis.
Tempus (NASDAQ:TEM) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference.
Founder and CEO Eric Lefkofsky is scheduled for a fireside chat at 2:00 p.m. ET on Monday, June 8, which will be accessible via a live webcast for investors and stakeholders.
Tempus (NASDAQ:TEM), Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center launched the IMS Open-Source Consortium to advance digital pathology. The group will develop an open-source image management platform and viewer, seeded by Tempus open-sourcing the clinical-grade Paige IMS, FullFocus viewer, FullFolio case manager, and AI modules.
Tempus (NASDAQ:TEM) announced upcoming clinical availability of xH, a whole-genome sequencing assay for hematologic malignancies, including AML, MDS, MPN, and MDS/MPN. The test uses NGS on blood and bone marrow to detect actionable oncologic targets.
Analytical validation on 235 specimens showed 97.29% PPA for SNVs/indels, 92.86% for SVs, and 93.43% for CNAs, with PPV of 98.97% for SNVs/indels and 100% for SVs. ASCO 2026 data in an MDS cohort showed >99% sensitivity and 40% more clinically relevant genomic findings versus traditional techniques. xH is expected to be commercially orderable later this year.